Advertisement Arcadia Biosciences Completes Commercial Production Of Nutritional Fatty Acid - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Arcadia Biosciences Completes Commercial Production Of Nutritional Fatty Acid

Arcadia Biosciences, a company focused on developing technologies and products that benefit human health, has completed its first commercial production of Sonova 400 High GLA Safflower Oil, an important nutritional omega-6 fatty acid with documented health benefits that are similar and complementary to the benefits of omega-3 fatty acids.

Reportedly, numerous published studies showed the benefits of GLA supplementation, including anti-inflammatory effects, and improved skin health and appearance. A recent study by Schirmer and Phinney found that GLA supplementation also plays a key role in maintaining weight loss.

Currently, evening primrose and borage oils are the two main sources of dietary GLA, containing 10% and 20% GLA, respectively. The availability of Sonova 400, with over 40% GLA – twice the GLA concentration of borage oil provides consumers with the option of taking fewer capsules or smaller capsules to obtain their desired level of GLA supplementation.

Arcadia Biosciences said that Sonova 400, developed through a combination of plant breeding and biotechnology, delivers 400mg of gamma-linolenic acid (GLA) per gram, making it a cost-effective source of GLA available.

Arcadia Biosciences has completed the FDA regulatory process for Sonova 400, allowing it to be marketed and sold as an ingredient in dietary supplements.

Eric Rey, president and CEO of Arcadia, said: “Completion of our first oil processing run represents one more successful step along the pathway to commercializing this important new product. Consumers and manufacturers have been asking for a more concentrated and cost-effective source of GLA.”